BioStock regarding TXP – December 20, 2022

BioStock – November 4, 2022

AP1189

A Novel and First-in-Class Agent to Target the Melanocortin System

Our drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors to help the body resolve inflammation. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by viruses like COVID-19.

A MESSAGE FROM OUR CEO

”It is exciting to see the company’s pipeline continue to advance and the business case around AP1189 strengthening.”